Evidence map›Paper›PMID 40535493›Full record

ArticleWorld journal of transplantation2025

C3 glomerulopathy post kidney transplantation: A single center experience.

Jonathan Zuckerman, Phuong-Thu Pham, Meena Parakkal, Alexis F Velazquez, Mrinalini Sarkar, Michael A Pablos, Suphamai Bunnapradist, Erik L Lum

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jonathan ZuckermanDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, United States.
Phuong-Thu PhamDepartment of Medicine, Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, United States.
Meena ParakkalDepartment of Medicine, Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, United States.
Alexis F VelazquezDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, United States.
Mrinalini SarkarDepartment of Medicine, Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, United States.
Michael A PablosDivision of Nephrology, Harbor Medical Center, University of California, Los Angeles, CA 90095, United States.
Suphamai BunnapradistDepartment of Medicine, Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, United States.
Erik L LumDepartment of Medicine, Division of Nephrology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, United States. elum@mednet.ucla.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundC3 glomerulopathies (C3G) are a rare cause of kidney failure resulting from complement dysregulation. Small studies demonstrate a high rate of recurrence and poor outcomes in kidney transplantation. Treatment efficacy in this setting with eculizumab, a terminal complement inhibitor, is largely unknown.

aimTo determine the outcomes of kidney transplantation in patients with C3G and the potential impact of eculizumab.

methodsWe retrospectively studied kidney transplant recipients who underwent a post-transplant biopsy confirming C3G between January 1, 1993 and December 31, 2023 at a single center. Only the first episode of kidney transplant was reviewed. The electronic medical records were reviewed for post-transplant allograft function, indication for biopsy, time to biopsy from transplant, time to allograft failure from transplantation, post-C3G treatment, complement laboratory testing, and concurrent malignancy/infection. Reports, and when available slides and immunofluorescence/electron microscopic images, were re-reviewed by a renal pathologist.

resultsA total of fifteen patients were included in this study. Fourteen patients had suspected recurrent disease, with a pre-transplant native kidney report of C3G. One patient developed

conclusionC3G following kidney transplantation is mostly a recurrent disorder with a poor prognosis in untreated patients. Untreated recurrence has a poor prognosis with median allograft survival < 2 years. Early treatment with eculizumab may improve transplant outcomes in patients with recurrent C3G.

Indexed as

C3 glomerulonephritisC3 glomerulopathyComplement disorderDense deposit diseaseKidney transplantRecurrent diseaseRenal pathology, Kidney biopsy

Identifiers

PMID40535493
PMCPMC11886292

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.